Aus Seeking Alpha:
Gilead's Epclusa OK'd in China; shares up 1% premarket
May 30, 2018 7:11 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
Gilead Sciences (NASDAQ:GILD) is up 1% premarket on light volume in response to its announcement that the China Food and Drug Administration (CFDA) has approved Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adults with chronic hepatitis C virus (HCV) infection genotypes 1-6.
The CFDA also approved Epclusa in combination with ribavirin for adults with HCV and decompensated cirrhosis.
About 10M Chinese are infected with HCV. Genotypes 1,2,3 and 6 account for more than 96% of all cases. |